

Gary W Falk

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5814225/gary-w-falk-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223
papers

13,502
citations

56
h-index

113
g-index

275
ext. papers

15,965
ext. citations

5.4
avg, IF

6.13
L-index

#	Paper	IF	Citations
223	International consensus recommendations for eosinophilic gastrointestinal disease nomenclature.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	3
222	The mast cell pain connection in eosinophilic esophagitis.. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022 ,	9.3	0
221	Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.. <i>American Journal of Gastroenterology</i> , 2022 , 117, 559-587	0.7	14
220	Eosinophilic Esophagitis: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1310-1318	17.1	4
219	Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer. <i>Scientific Reports</i> , 2021 , 11, 21304	4.9	2
218	Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 321-326	3	4
217	Type II achalasia is associated with a comparably favorable outcome following per oral endoscopic myotomy. <i>Ecological Management and Restoration</i> , 2021 , 34,	3	3
216	<i>Helicobacter pylori</i> and GERD 2021 , 419-427		
215	Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	12
214	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	
213	Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
212	Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
211	Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2021 , 93, 1250-1257.e3	5.2	5
210	Best Practices in Surveillance for Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021 , 31, 59-75	3.3	4
209	Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
208	Age of diagnosis in familial Barrett's associated neoplasia. <i>Familial Cancer</i> , 2021 , 1	3	0
207	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2021 ,	11.5	4

206	Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2021 ,	5.2	2
205	Transition of Care from Pediatric to Adult Care in Eosinophilic Esophagitis: Insights From a Patient Perspective Survey. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021 , 73, 722-726	2.8	
204	Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 750-759	6.1	13
203	Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 1629-1640.e4	11.5	15
202	Modeling Epithelial Homeostasis and Reactive Epithelial Changes in Human and Murine Three-Dimensional Esophageal Organoids. <i>Current Protocols in Stem Cell Biology</i> , 2020 , 52, e106	2.8	6
201	Is the age of diagnosis of esophageal adenocarcinoma getting younger? Analysis at a tertiary care center. <i>Ecological Management and Restoration</i> , 2020 , 33,	3	1
200	Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. <i>Gastrointestinal Endoscopy</i> , 2020 , 92, 31-39.e1	5.2	18
199	Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma. <i>Gastroenterology</i> , 2020 , 159, 575-590	13.3	23
198	Virtual Dysphagia Evaluation: Practical Guidelines for Dysphagia Management in the Context of the COVID-19 Pandemic. <i>Otolaryngology - Head and Neck Surgery</i> , 2020 , 163, 455-458	5.5	21
197	An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1869-1878	0.7	10
196	Novel Therapeutic Approaches to Eosinophilic Esophagitis. <i>Gastroenterology and Hepatology</i> , 2020 , 16, 294-301	0.7	
195	Low Yield of Cross-Sectional Imaging in Patients With Esophagogastric Junction Outflow Obstruction. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1643-1644	6.9	14
194	Persistent Basal Cell Hyperplasia Is Associated With Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1475-1482.e1	6.9	9
193	Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 255-269	11.5	19
192	Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 2024-2035	4	17
191	High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020 , 71, 524-529	2.8	4
190	Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020 , 158, 111-122.e10	13.3	135
189	Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids. <i>Current Protocols in Stem Cell Biology</i> , 2020 , 53, e109	2.8	11

188	Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF- α . <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 171-182	11.5	19
187	High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. <i>International Journal of Cancer</i> , 2019 , 145, 2754-2766	7.5	5
186	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1477-1488.e10	6.9	6
185	Barrett's Esophagus 2019 , 279-290.e5		1
184	Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 864-868	6.9	34
183	Overestimation of the diagnosis of eosinophilic colitis with reliance on billing codes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 2434-2436	5.4	0
182	Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. <i>Oncotarget</i> , 2019 , 10, 3592-3604	3.3	5
181	Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development. <i>EBioMedicine</i> , 2019 , 49, 145-156	8.8	5
180	Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium. <i>American Journal of Gastroenterology</i> , 2019 , 114, 984-994	0.7	38
179	Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium. <i>Gastrointestinal Endoscopy</i> , 2019 , 89, 257-263.e3	5.2	11
178	2017 David Sun Lecture: Screening and Surveillance of Barrett's Esophagus: Where Are We Now and What Does the Future Hold?. <i>American Journal of Gastroenterology</i> , 2019 , 114, 64-70	0.7	2
177	Achalasia Patients Are at Nutritional Risk Regardless of Presenting Weight Category. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 1243-1249	4	10
176	Clinical Guidelines Update on the Diagnosis and Management of Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2122-2128	4	24
175	The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018 , 5, 333-352	7.9	41
174	Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. <i>Gastroenterology</i> , 2018 , 154, 1282-1289.e2	13.3	69
173	Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 477-488	18.8	57
172	Cryotherapy and Radiofrequency Ablation for Eradication of Barrett's Esophagus with Dysplasia or Intramucosal Cancer. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 1311-1319	4	26
171	Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 495-503.e8	6.9	48

170	Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 348-355	5.2	71
169	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018 , 155, 1022-1033.e10	13.3	367
168	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 130-138.e1	11.5	25
167	Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis. <i>Gut</i> , 2017 , 66, 1197-1207	19.2	27
166	Columnar islands in Barrett's esophagus: Do they impact Prague C&M criteria and dysplasia grade?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1598-1603	4	4
165	Modeling Esophagitis Using Human Three-Dimensional Organotypic Culture System. <i>American Journal of Pathology</i> , 2017 , 187, 1787-1799	5.8	4
164	Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1032-1048	0.7	24
163	Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>Gastrointestinal Endoscopy</i> , 2017 , 86, 1-17.e3	5.2	32
162	Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. <i>Gastroenterology</i> , 2017 , 153, 681-688.e2	13.3	67
161	Proton pump inhibitor-responsive oesophageal eosinophilia: too early to change clinical practice. <i>Gut</i> , 2017 , 66, 979-980	19.2	9
160	A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 240-248	4	22
159	Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy. <i>Gastroenterology</i> , 2017 , 152, 987-992	13.3	40
158	Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. <i>PLoS ONE</i> , 2017 , 12, e0184962	3.7	5
157	Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Translational Science of Rare Diseases</i> , 2017 , 2, 141-155	3.3	17
156	Presentation of the Julius M. Friedenwald Medal to Anil K. Rustgi. <i>Gastroenterology</i> , 2017 , 152, 2063-2067	7.3	
155	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2017 , 152, 776-786.e5	13.3	114
154	Current Management of Low-Grade Dysplasia in Barrett Esophagus. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 221-225	0.7	2
153	Esophageal cancer: The latest on chemoprevention and state of the art therapies. <i>Pharmacological Research</i> , 2016 , 113, 236-244	10.2	22

152	ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2016 , 111, 151-3	0.7	10
151	Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 727-35	4	9
150	Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet?. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 1011-1014	11.5	27
149	ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2016 , 111, 30-50; quiz 51	0.7	928
148	Updated Guidelines for Diagnosing and Managing Barrett Esophagus. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 449-51	0.7	3
147	Eosinophilic Esophagitis-Associated Chemical and Mechanical Microenvironment Shapes Esophageal Fibroblast Behavior. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016 , 63, 200-9	2.8	21
146	Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. <i>Molecular Carcinogenesis</i> , 2016 , 55, 1526-1541	5	15
145	A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 958-68	4	28
144	Four Approaches to Reinvigorate Learning for the 21st Century Gastroenterologist. <i>Gastroenterology</i> , 2016 , 151, 218-21	13.3	
143	Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1842-1844	6.9	14
142	Findings of Esophagography for 25 Patients After Peroral Endoscopic Myotomy for Achalasia. <i>American Journal of Roentgenology</i> , 2016 , 207, 1185-1193	5.4	13
141	Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas. <i>Molecular Genetics & Genomic Medicine</i> , 2016 , 4, 407-19	2.3	4
140	Barrett's oesophagus: frequency and prediction of dysplasia and cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2015 , 29, 125-38	2.5	7
139	Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 412-6	5.1	12
138	Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2015 , 81, 1158-66.e1-4	5.2	27
137	Associations of Serum Adiponectin and Leptin With Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2265-72	6.9	16
136	Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 665-72.e1-4	6.9	35
135	The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on peroral endoscopic myotomy. <i>Gastrointestinal Endoscopy</i> , 2015 , 81, 1087-100.e1	5.2	37

134	BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015 , 110, 662-82; quiz 683	0.7	92
133	Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , 2015 , 44, 299-315	4.4	10
132	An Unusual Cause of Abdominal Pain. Appendiceal Intussusception Owing to Cecal Adenocarcinoma. <i>Gastroenterology</i> , 2015 , 149, e1-2	13.3	1
131	Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study. <i>Endoscopy</i> , 2015 , 47, 669-74	3.4	19
130	Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. <i>Gastroenterology</i> , 2015 , 149, 1599-606	13.3	61
129	Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. <i>Gastroenterology</i> , 2015 , 149, 567-76.e3; quiz e13-4	13.3	65
128	Barrett's oesophagus length is established at the time of initial endoscopy and does not change over time: results from a large multicentre cohort. <i>Gut</i> , 2015 , 64, 1874-80	19.2	9
127	Selection of patients for cancer prevention and eradication 2015 , 209-220		
126	Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1143-8	0.7	4
125	Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition. <i>Experimental Cell Research</i> , 2015 , 330, 102-10	4.2	27
124	Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , 2015 , 44, xiii	4.4	1
123	Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015 , 44, xiii	4.4	1
122	BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1557-68	15.9	61
121	Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. <i>Oncotarget</i> , 2015 , 6, 32980-3005	3.3	6
120	Update on ablation for Barrett's esophagus. <i>Current Gastroenterology Reports</i> , 2014 , 16, 368	5	
119	Management of early-stage esophageal neoplasia (MESEN) consensus. <i>World Journal of Surgery</i> , 2014 , 38, 96-105	3.3	1
118	Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. <i>Experimental Biology and Medicine</i> , 2014 , 239, 1108-23	3.7	13
117	T-helper 2 cytokines, transforming growth factor β , and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis. <i>Gastroenterology</i> , 2014 , 146, 1266-77.e13	13.3	92

116	Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2014 , 80, 71-7	5.2	37
115	In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). <i>Gastrointestinal Endoscopy</i> , 2014 , 79, 211-21	5.2	153
114	Radiofrequency ablation for Barrett's esophagus. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 415-21	3	1
113	Clinical presentation of eosinophilic esophagitis in adults. <i>Gastroenterology Clinics of North America</i> , 2014 , 43, 231-42	4.4	12
112	Eosinophilic esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014 , 43, xiii	4.4	1
111	Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. <i>Nature Medicine</i> , 2013 , 19, 1005-13	50.5	271
110	Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. <i>Gastrointestinal Endoscopy</i> , 2013 , 77, 190-9	5.2	46
109	Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1430-6	6.9	99
108	Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. <i>Gastroenterology</i> , 2013 , 145, 79-86.e1	13.3	189
107	Modeling inflammation and oxidative stress in gastrointestinal disease development using novel organotypic culture systems. <i>Stem Cell Research and Therapy</i> , 2013 , 4 Suppl 1, S5	8.3	24
106	Location, location, location: does early cancer in Barrett's esophagus have a preference?. <i>Gastrointestinal Endoscopy</i> , 2013 , 78, 462-7	5.2	36
105	Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. <i>Gastroenterology</i> , 2013 , 145, 548-53.e1	13.3	69
104	Update on the use of radiofrequency ablation for treatment of barrett esophagus. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 447-9	0.7	
103	Subsquamous intestinal metaplasia: implications for endoscopic management of Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 220-4	6.9	13
102	Diseases of the Esophagus 2012 , 874-886		
101	Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. <i>Gastroenterology</i> , 2012 , 143, 336-46	13.3	305
100	Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. <i>Gastroenterology</i> , 2012 , 143, 564-566.e1	13.3	109
99	A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. <i>Gastroenterology</i> , 2012 , 143, 917-26.e1	13.3	50

98	The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus. <i>Gastrointestinal Endoscopy</i> , 2012 , 76, 252-4	5.2	120
97	Poor discriminatory function for endoscopic skills on a computer-based simulator. <i>Gastrointestinal Endoscopy</i> , 2012 , 76, 993-1002	5.2	15
96	Variation in age at cancer diagnosis in familial versus nonfamilial Barrett's esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 376-83	4	24
95	Association of insulin and insulin-like growth factors with Barrett's oesophagus. <i>Gut</i> , 2012 , 61, 665-72	19.2	63
94	Diagnosis and Surveillance of Barrett's Esophagus 2012 , 321-339		
93	Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. <i>Gastroenterology</i> , 2011 , 141, 1179-86, 1186.e1	13.3	198
92	Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. <i>Gastroenterology</i> , 2011 , 141, 460-8	13.3	367
91	Eosinophilic esophagitis: updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011 , 128, 3-20.e6; quiz 21-2	11.5	1502
90	Barrett's esophagus: surveillance and reversal. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1232, 196-209	6.5	3
89	Barrett's esophagus: prevalence-incidence and etiology-origins. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1232, 1-17	6.5	23
88	Barrett's esophagus: endoscopic diagnosis. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1232, 53-75	6.5	11
87	Barrett's esophagus surveillance: When, how often, does it work?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011 , 21, 9-24	3.3	5
86	Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 220-7; quiz e26	6.9	174
85	Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, G571-81	5.1	78
84	A segregation analysis of Barrett's esophagus and associated adenocarcinomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 666-74	4	36
83	Cutting to the chase: circumferential endoscopic mucosal resection for Barrett's neoplasia. <i>Gut</i> , 2010 , 59, 1163-4	19.2	2
82	Evidence for DNA damage checkpoint activation in barrett esophagus. <i>Translational Oncology</i> , 2010 , 3, 33-42	4.9	6
81	M1104 Predicting High-Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter Cohort Study. <i>Gastroenterology</i> , 2010 , 138, S-333	13.3	2

80	92 Durability of Epithelial Reversion After Radiofrequency Ablation: Follow-up of the AIM Dysplasia Trial. <i>Gastroenterology</i> , 2010 , 138, S-16-S-17	13.3	4
79	Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?. <i>Gastroenterology</i> , 2010 , 139, 377-9	13.3	3
78	The role of allergy evaluation in adults with eosinophilic esophagitis. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 22-7	3	65
77	Management of nondysplastic Barrett's esophagus: where are we now?. <i>American Journal of Gastroenterology</i> , 2009 , 104, 805-8	0.7	21
76	Assessment of familiarity, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1913-21	0.7	40
75	Radiofrequency ablation in Barrett's esophagus with dysplasia. <i>New England Journal of Medicine</i> , 2009 , 360, 2277-88	59.2	1097
74	An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. <i>Gastrointestinal Endoscopy</i> , 2009 , 70, 635-44	5.2	142
73	Radiofrequency ablation of Barrett's esophagus: should everybody get it?. <i>Gastroenterology</i> , 2009 , 136, 2399-401; discussion 2401-2	13.3	5
72	Antireflux therapy in asthma: is there any role?. <i>Gastroenterology</i> , 2009 , 137, 1844-6	13.3	1
71	Autofluorescence endoscopy. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009 , 19, 209-20	3.3	35
70	The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 653-8; quiz 606	6.9	79
69	Risk factors for esophageal cancer development. <i>Surgical Oncology Clinics of North America</i> , 2009 , 18, 469-85	2.7	78
68	Role of barium esophagography in evaluating dysphagia. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76, 105-11	2.8	15
67	Decision Making in Ablation: Disease, Patients, and Institutional Factors 2009 , 63-89		
66	213 A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (Be) Containing Dysplasia: Interim Results of the Aim Dysplasia Trial. <i>Gastroenterology</i> , 2008 , 134, A-37	13.3	12
65	Obesity and gastroesophageal reflux disease: another piece of the puzzle. <i>Gastroenterology</i> , 2008 , 134, 1620-2	13.3	5
64	Refractory GERD: further insights into the cause of symptoms. <i>Gastroenterology</i> , 2008 , 135, 1414-5	13.3	3
63	Is conventional endoscopic identification of non-erosive reflux disease adequate?. <i>Digestion</i> , 2008 , 78 Suppl 1, 17-23	3.6	11

62	Chemoprevention and Barrett's esophagus: decisions, decisions. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2443-5	0.7	7
61	Eosinophilic esophagitis: an increasingly recognized cause of dysphagia, food impaction, and refractory heartburn. <i>Cleveland Clinic Journal of Medicine</i> , 2008 , 75, 623-6, 629-33	2.8	16
60	Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma. <i>Translational Research</i> , 2007 , 150, 3-17	11	12
59	Laryngopharyngeal reflux: beauty is in the eye of the beholder. <i>Gastroenterology</i> , 2007 , 133, 1379-81	13.3	4
58	How exactly do i diagnose intestinal metaplasia in Barrett's esophagus?. <i>Gastroenterology</i> , 2007 , 133, 2060-2; discussion 2062	13.3	2
57	Extent of low-grade dysplasia in Barrett's esophagus: is it useful for risk stratification?. <i>American Journal of Gastroenterology</i> , 2007 , 102, 494-6	0.7	17
56	Is FDG-PET indicated for superficial esophageal cancer?. <i>European Journal of Cardio-thoracic Surgery</i> , 2007 , 31, 791-6	3	43
55	Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. <i>Cancer</i> , 2006 , 107, 2160-6	6.4	69
54	Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1668-73	4	93
53	Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2187-93	0.7	60
52	Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1964-71	0.7	56
51	Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 566-72	6.9	334
50	AGA Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. <i>Gastroenterology</i> , 2006 , 131, 1313-4	13.3	14
49	AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. <i>Gastroenterology</i> , 2006 , 131, 1315-36	13.3	44
48	Eosinophilic esophagitis: new insights into an emerging disease. <i>Gastroenterology</i> , 2006 , 131, 2018-20; discussion 2020	13.3	5
47	Eosinophilic pancreatitis presenting as a pancreatic mass with obstructive jaundice. <i>Gastrointestinal Endoscopy</i> , 2006 , 63, 525-7	5.2	9
46	Turning an idea into a grant. <i>Gastrointestinal Endoscopy</i> , 2006 , 64, S11-3	5.2	4
45	Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 1089-94	6.9	33

44	Esophageal manometry: assessment of interpreter consistency. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 218-24	6.9	44
43	Barrett's esophagus-is it bad for your health?. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2622-3	0.7	8
42	Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. <i>Modern Pathology</i> , 2004 , 17, 588-96	9.8	53
41	A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. <i>Gastroenterology</i> , 2004 , 127, 310-30	13.3	521
40	Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. <i>Gastrointestinal Endoscopy</i> , 2004 , 60, 280-4	5.2	28
39	A coxib a day won't keep the doctor away. <i>Lancet, The</i> , 2004 , 364, 639-40	4.0	63
38	Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. <i>Digestive Diseases and Sciences</i> , 2003 , 48, 1537-41	4	81
37	Cytology in Barrett's esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2003 , 13, 335-48	3.3	15
36	Motility and GI function studies billing and coding guidelines: a position paper of the American Motility Society. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1228-36	0.7	8
35	Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. <i>American Journal of Gastroenterology</i> , 2002 , 97, 302-11	0.7	66
34	Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1340-5	0.7	37
33	p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2508-13	0.7	109
32	Barrett's esophagus. <i>Gastroenterology</i> , 2002 , 122, 1569-91	13.3	311
31	Superficial adenocarcinoma of the esophagus. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001 , 122, 1077-90	1.5	136
30	Pathogenesis of gastroesophageal reflux and Barrett esophagus. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 226-34	6.4	31
29	Progression of Barrett's esophagus to high grade dysplasia and cancer: Preliminary results of the BEST (Barrett's esophagus study) trial. <i>Gastroenterology</i> , 2001 , 120, A16-A17	13.3	9
28	Pathogenesis of Gastroesophageal Reflux and Barrett Esophagus. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 226-234	6.4	3
27	Adenocarcinoma in Barrett's Esophagus: Signs, Symptoms and Endoscopic Appearance 2001 , 291-295		

26	Unresolved issues in Barrett's esophagus in the new millennium. <i>Digestive Diseases</i> , 2000 , 18, 27-42	3.2	11
25	CagA-positive strains of <i>Helicobacter pylori</i> may protect against Barrett's esophagus. <i>American Journal of Gastroenterology</i> , 2000 , 95, 2206-11	0.7	142
24	The gastric cardia: fact or fiction?. <i>American Journal of Gastroenterology</i> , 2000 , 95, 921-4	0.7	204
23	Endoscopic surveillance of Barrett's esophagus. <i>Techniques in Gastrointestinal Endoscopy</i> , 2000 , 2, 186-193	3.8	4
22	Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. <i>Gastroenterology</i> , 2000 , 119, 683-90	13.3	102
21	Practice patterns for surveillance of Barrett's esophagus in the united states. <i>Gastrointestinal Endoscopy</i> , 2000 , 52, 197-203	5.2	123
20	The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2037-42	0.7	112
19	Role of <i>Helicobacter pylori</i> cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. <i>International Journal of Cancer</i> , 1999 , 82, 520-4	7.5	52
18	Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , 1999 , 49, 170-6	5.2	262
17	Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. <i>Gastrointestinal Endoscopy</i> , 1999 , 49, S29-34	5.2	26
16	The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's esophagus registry. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2037-2042	0.7	206
15	Gastroesophageal reflux disease. <i>Current Opinion in Gastroenterology</i> , 1999 , 15, 333-8	3	2
14	Why is esophageal adenocarcinoma increasing in incidence?. <i>Abdominal Imaging</i> , 1998 , 23, 539-42		3
13	The seroprevalence of cagA-positive <i>Helicobacter pylori</i> strains in the spectrum of gastroesophageal reflux disease. <i>Gastroenterology</i> , 1998 , 115, 50-7	13.3	314
12	Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and <i>H. pylori</i> infection. <i>Gastroenterology</i> , 1998 , 114, 633-9	13.3	238
11	<i>Helicobacter pylori</i> and gastroesophageal reflux disease: the bug may not be all bad. <i>American Journal of Gastroenterology</i> , 1998 , 93, 1800-2	0.7	74
10	Effect of pneumatic dilation on gastroesophageal reflux in achalasia. <i>Digestive Diseases and Sciences</i> , 1997 , 42, 998-1002	4	18
9	Observer variation and reproducibility of endoscopic ultrasonography. <i>Gastrointestinal Endoscopy</i> , 1995 , 41, 115-20	5.2	65

8	Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1994 , 4, 773-789	3.3	18
7	p53 Immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1994 , 108, 1132-1137	1.5	40
6	Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , 1994 , 40, 207-12	5.2	91
5	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , 1992 , 37, 1927	4	
4	Effect of ozone and nitrogen dioxide on the agglutination of rat alveolar macrophages by concanavalin A. <i>Life Sciences</i> , 1977 , 21, 1637-44	6.8	16
3	Surveillance of Barrett's Esophagus107-123		
2	Barrett's Esophagus509-539		
1	Barrett's Esophagus287-309		0